What Researchers Did
This review summarized existing research on how to manage chronic pouchitis that doesn't respond to standard antibiotic treatments after restorative proctocolectomy.
What They Found
Researchers found that mesalamine improved symptoms but not quality of life, while budesonide showed high rates of sustained clinical remission in a small group of patients. Anti-tumor necrosis factor therapies were effective clinically and endoscopically, though many patients stopped treatment. Vedolizumab showed favorable results across several measures, including in a randomized, placebo-controlled trial, and hyperbaric oxygen therapy and fecal microbiota transplant have undergone limited evaluation.
What This Means for Canadian Patients
For Canadian patients suffering from chronic pouchitis that hasn't responded to standard antibiotics, this review highlights various treatment options. It suggests that drugs like vedolizumab and budesonide may offer relief, while other therapies like hyperbaric oxygen therapy are still being explored.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a narrative review, this study summarizes existing evidence without performing a new statistical analysis, and some non-medication therapies like HBOT had only limited evaluation.